Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder [0.03%]
一种罕见出血性疾病——platelet-type血管性血友病的三十年变迁
Maha Othman
Maha Othman
Almost thirty years has passed since the description of platelet-type von Willebrand disease. Named initially pseudo-von Willebrand disease, this mild mucocutaneous bleeding disorder has an intrinsic defect in platelets rather than VWF. Due...
Katleen Broos,Hendrik B Feys,Simon F De Meyer et al.
Katleen Broos et al.
When platelet numbers are low or when their function is disabled, the risk of bleeding is high, which on the one hand indicates that in normal life vascular damage is a rather common event and that hence the role of platelets in maintaining...
Thorsten Zenz,Daniel Mertens,Hartmut Döhner et al.
Thorsten Zenz et al.
Recurrent losses or gains of genomic material as well as mutations of key tumor suppressors (ATM and TP53) have been identified in chronic lymphocytic leukemia (CLL). These aberrations are important "drivers" of the disease and some of its ...
Interpretation of cytogenetic and molecular results in patients treated for CML [0.03%]
慢性粒细胞白血病患者的细胞遗传学和分子生物学结果解读
Carlos E Vigil,Elizabeth A Griffiths,Eunice S Wang et al.
Carlos E Vigil et al.
The International Randomized Study of Interferon vs. STI571 (IRIS) trial that investigated the use of the tyrosine kinase inhibitor (TKI) imatinib (versus interferon) changed the treatment and outcome of chronic myeloid leukemia (CML). Long...
Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials [0.03%]
抗血小板和抗凝联合治疗的有效性和安全性：随机对照试验的证据批判性综述
Jeremy S Paikin,Doug S Wright,John W Eikelboom
Jeremy S Paikin
Antiplatelet and anticoagulant drugs are effective for the prevention of arterial and venous thrombosis but patients continue to experience major cardiovascular events despite their use. Strategies to improve the effectiveness of antithromb...
Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia [0.03%]
严重由治疗引起的细胞减少症患者血小板输注的优化措施现状及未来方向
Torunn O Apelseth,Tor Hervig,Oystein Bruserud
Torunn O Apelseth
Platelet transfusions are mainly used for patients with thrombocytopenia due to bone marrow failure, especially cancer patients developing severe chemotherapy-induced thrombocytopenia (e.g. patients with acute leukemia or other hematologic ...
Plasma cell leukemia [0.03%]
plasma细胞白血病
Flavio Albarracin,Rafael Fonseca
Flavio Albarracin
Plasma cell leukemia (PCL) is a rare, yet aggressive plasma cell (PC) neoplasm, variant of multiple myeloma (MM), characterized by high levels of PCs circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as ...
Francesca Gay,Antonio Palumbo
Francesca Gay
For many years, the oral combination melphalan-prednisone (MP) has been considered the standard of care for patients with multiple myeloma (MM) not eligible for autologous stem cell transplantation. In the era of novel agents, the introduct...
Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies [0.03%]
慢性淋巴细胞白血病的同种异体干细胞移植：需从微小残留病研究中汲取的经验教训
Sebastian Böttcher,Matthias Ritgen,Peter Dreger
Sebastian Böttcher
Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment strategy for poor-risk chronic lymphocytic leukemia (CLL). The crucial anti-leukemic principle of alloSCT in CLL appears to be the graft-versus-leukemia effe...
Rolf T Urbanus,Philip G de Groot
Rolf T Urbanus
The diagnosis of antiphospholipid syndrome is predominantly made in the laboratory and depends on the persistent presence of antiphospholipid antibodies in individuals with thrombosis or pregnancy morbidity. Correct diagnosis of the syndrom...